|
Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress. |
|
|
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks |
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Celgene Cancer Care Links/BMS; Eisai; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER |
Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Eisai; Menarini; Sanofi; SERVIER |
Research Funding - Dong-A ST; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Celgene; Merck Serono; SERVIER |
Speakers' Bureau - Celgene |
Research Funding - Celgene; medpacto; SERVIER |